
Full text loading...
Extracted from text ... A Food and Drug Administration advi-sory panel unanimously recommended that carvedilol receive an indication for mortality reduction post acute myocar-dial infarction in patients with left ven-tricular ejection fraction less than 41%. However, panel chairman Jeffrey Borer, MD, chief of the Division of Cardiovascular Pathology at Weill Medical College, cautioned the agency that this recommendation should not be universally applied to other drugs. 'Ultimately, we have to consider each application on the merits and details, and the FDA should not assume that our decision here can be extrapolated to all related situations, ' Borer said. Borer's concern was based on the ..
Article metrics loading...